Publications by authors named "M D Neely"
The lungs of patients with cystic fibrosis (CF) are vulnerable to persistent polymicrobial colonization by bacterial pathogens including , and the non-tuberculous mycobacterium (NTM) . The polymicrobial milieu within the CF lung impacts individual species fitness, influences biofilm-forming capabilities, pathogenicity, production of virulence factors and even antimicrobial responses, all potentially compromising therapeutic success. Interaction studies among these CF pathogens are very limited, especially studies on the influences of and on co-existence and virulence.
View Article and Find Full Text PDFBackground: Basiliximab induction immunosuppression is increasingly employed in lung transplant recipients despite limited prospective evidence to support its use in this population. We sought to determine the relationship between basiliximab induction and development of acute rejection, chronic lung allograft dysfunction, and other clinically relevant outcomes in a multicenter lung transplant cohort with variable induction practice patterns.
Methods: We applied propensity-based statistical methods to rigorous, prospectively collected longitudinal data from 768 newly transplanted adult lung recipients at 5 North American centers (368 who received basiliximab induction immunosuppression and 400 who received no induction immunosuppression).
Background: Understanding donor factors associated with successful lung transplantation (LTx) following donation after circulatory death (DCD) is important in optimizing donor management. In this study, we examined critical care and ventilatory factors associated with DCD LTx and allograft survival using a unique detailed donor management database.
Methods: The Donor Management Goals national registry was queried for DCD donors between January 2016 and July 2023.
Article Synopsis
- Invasive aspergillosis (IA) and mucormycosis (IM) significantly affect severely ill patients, prompting the approval of isavuconazonium sulfate for treating these fungal infections in both adults and recently in children.
- A phase 2 study involved 31 pediatric patients across multiple countries, revealing a 54.8% overall response rate to treatment and a low 6.5% all-cause case fatality at 42 days.
- Although 93.5% of participants experienced treatment-emergent adverse events (TEAEs), the drug was generally well tolerated, and dosing conformed to safety standards previously established in adult studies.